National Trends in Diabetes Medication Use in the United States: 2008 to 2015.
Autor: Raval, Amit D.; Vyas, Ami
Publication year: 2020
Journal of pharmacy practice
issn:1531-1937 0897-1900
doi: 10.1177/0897190018815048
Abstract:
BACKGROUND: Data on trends of diabetes medications use are sparse, outdated, and limited to prescription data. We determined trends in diabetes medication use among US individuals with diabetes during 2008-2015. METHODS: We used 2008-2015 Medical Expenditure Panel Survey to examine diabetes medication utilization among individuals aged ≥18 years with diabetes. Prescription medications were classified based on therapeutic class and subclass using Multum Lexicon database. RESULTS: From 2008 to 2015, use of any diabetes medication (81.4% vs. 87%), metformin (47.8% vs. 59.0%), and insulin (23.0% vs. 31.0%) increased, whereas, use of sulfonylurea (36.0% vs. 29.0%) and thiazolidinedione (21% vs. 9.0%) declined. A linear increase was observed in the uptake of dipeptidyl peptidase-4 (DPP-4) inhibitors from 6.2% in 2008 to 12.4% in 2015; glucagon-like peptide-1 (GLP-1) receptor agonists from 2.5% in 2008 to 4.4% in 2015 and sodium glucose transporter-2 (SGLT2) inhibitors from 0.8% in 2014 (the first SGLT2 inhibitors approval year) to 4.4% in 2015. Monotherapy use increased from 50.6% to 56.4% during 2008-2015, while triple therapy use declined. CONCLUSIONS: Metformin, insulin and sulfonylureas remained the top-three prescribed classes of diabetes medications. Increased use of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors was offset by decline in TZDs use.
Language: eng
Rights:
Pmid: 30572757
Tags: Humans; Adult; Adolescent; United States/epidemiology; diabetes; Hypoglycemic Agents/therapeutic use; Metformin; trends; Medical Expenditure Panel Survey; insulin; metformin; *Diabetes Mellitus/drug therapy/epidemiology; Dipeptidyl-Peptidase IV Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds
Link: https://pubmed.ncbi.nlm.nih.gov/30572757/
